Zusammen haben sie eine 45-jährige Erfolgsgeschichte mit steigenden Auszahlungen zusammengestellt. Market value: $124.0 billion. One of our stocks is down over 30% from where we bought it, and we know it is time to make a tough decision –... High dividend stocks are popular holdings in retirement portfolios. Pharmaceutical giant AbbVie (ABBV, $92.38) is about as stalwart a dividend grower as they come. Pharmaceutical sales, earnings, and cash flow are usually quite defensive thanks to the high margins of patent-protected drugs and the non-discretionary nature of healthcare spending to fight various illnesses. Regarding the acquisition, AbbVie CEO Richard Gonzalez said: You look at [the drugs] Skyrizi, Rinvoq, Venclexta, Imbruvica. The Motley Fool has a disclosure policy. It focuses on a few key treatment areas, including … This article will look at a few key metrics along with future growth prospects to determine ABBV dividend safety. Pharmaceutical maker AbbVie (NYSE: ABBV) has been caught in the downdraft, down 7% since the beginning of the year. At the company-specific level, AbbVie has faced pressure as well. Which category does AbbVie fall into, and is the dividend safe? Das Biotechnologie- und Pharmaunternehmen Abbvie, eigene Schreibweise AbbVie, wurde 2013 als Abspaltung von Abbott Laboratories gegründet und wird an der New Yorker Börse NYSE im S&P-100-Index unter dem Symbol „ABBV“ gehandelt. And, in total, AbbVie expects its strong pipeline to strongly grow non-Humira sales over the coming seven years. Those all have significant growth opportunities ahead of them on the AbbVie side. Spun off from Abbott Laboratories (NYSE: ABT) in 2013, AbbVie has grown annual revenue from $18.8 billion that year to $33.3 billion in 2019. In short, yes. AbbVie reported strong 2019 year-end results on Feb. 7. I think Abbvie will deliver very nice returns for investors. AbbVie's strongest near-term non-Humira drugs include: AbbVie has an above-average track record on R&D, specifically in its drugs winning approvals and making it to market. - Intelligent Income by Simply Safe Dividends Is AbbVie's Dividend Safe? This news broke on the same day as the 80% Humira EU price cut. Recent market volatility has unfairly whipsawed many stocks that are usually considered steady eddies, and the effects have been even stronger for specific sectors and speculative stocks. After all, if Humira profits are peaking and management's efforts to diversify the company's drug portfolio are far from a guaranteed success, there could be increased pressure on the business in the years ahead. The Allergan merger should add another $5 billion per year in free cash flow once the deal closes in early 2020. App Economy Insights Dec. 30, 2020 10:45 AM ET. AbbVie gave its payout a mighty boost just ahead of a major trial failure. The first major blow came in late March 2018, when disappointing drug trial results came out for the firm's promising Rova-T cancer drug. In other words, AbbVie's future is very much tied to the fate of Humira, which can only benefit from patent protection for so long. Any part of your body can be mistakenly attacked, resulting in conditions like lupus, Crohn's disease, rheumatoid arthritis, chronic plaque psoriasis, and other illnesses. However, it’s still hard to get comfortable with AbbVie… Specifically, FDA Commissioner Scott Gottlieb has said he wants to accelerate how quickly generic and biosimilar drugs get approved. AbbVie Inc.'s (NYSE: ABBV) treated shareholders to some hefty dividend bumps since its inception five years ago, but a 35% raise announced in February was the biggest yet. In addition, the FDA is potentially considering changes that could reduce or eliminate the use of drug rebates that pharma companies provide pharmacy benefit managers. A larger than expected price cut on Humira in the EU will likely reduce both management guidance and analyst growth expectations a bit. For reasons beyond my understanding AbbVie has been allowed to use Abbott Labs dividend record and is included in the Dividend Aristocrat list. Das Wachstum ist ebenfalls gesund, einschließlich der jüngsten Steigerung der AbbVie-Auszahlung um … Learn about the 15 best high yield stocks for dividend income in March 2020. 25'' list, signifying a stock with above-average ''DividendRank'' statistics … It has a $130 billion market capitalization, and sells its products in more than 170 countries across the world. 2 Top Picks - Safe High Dividend Biotechs For 2021. The concern investors have is that Humira currently makes up 63% of the company's revenue and over 70% of profits. However, just because a dividend isn't at strong risk of being cut doesn't necessarily mean a high-yield stock is worth buying. Let's take a closer look at the factors that continue supporting AbbVie's payout. A score of 50 is average, 75 or higher is excellent, and 25 or lower is weak. Payout ratio calculation and chart. So what do all of these developments mean for AbbVie's dividend safety? Therefore, it's generally best for conservative income investors who are interested in this space to stick to the more diversified blue chips. Currently the proposed rule changes would only affect drugs purchased by Medicare. Show full articles without "Continue Reading" button for {0} hours. It already faces biosimilar competition in Europe, and will lose U.S. patent protection in 2023. This is a product that is about an $850 million product. Not long after announcing the payout boost and another $10 billion stock repurchase program, a high-profile clinical trial failure knocked AbbVie's stock down a few pegs.. At recent prices, AbbVie shares offer a nice 4% yield. Those with strong balance sheets, balanced drug portfolios, and a good track record of delivering safe and growing dividends. Pfizer announced on Monday its COVID-19 vaccine candidate was found to be more than 90% effective, and no serious safety concerns had... Dominion's Lower Dividend and New Business Mix Improve Safety Profile; We Plan to Hold Our Shares. Find the latest dividend history for AbbVie Inc. Common Stock (ABBV) at Nasdaq.com. Strong growth came from Imbruvica, which grossed sales of $4.7 billion, up 30% from the previous year. The AbbVie dividend has been paid continuously since 1924 and increased for 48 consecutive years; qualifying the company as a Dividend Aristocrat. Besides the overhang of Humira's growth trajectory in international markets, adding to the selling pressure was news that the FDA just approved Novartis' (NVS) biosimilar Myrimoz for sale in the U.S. AbbVie Inc (Symbol: ABBV) has been named to the Dividend Channel ''S.A.F.E. Humira is a pretty big blockbuster, and the reason is its ability to block the body's inflammatory process. AbbVie’s Dividend Safety Relative to Free Cash Flow AbbVie stock has sported an attractive dividend yield since its 2012 spinoff from Abbott. Out of Ignorance Dec. 30, 2020 6:12 AM ET. I think the last numbers I saw showed it was growing about 70%. If those are too high, might that not force management to cut the dividend in order to retain more cash to deleverage and diversify and the company's drug portfolio? There are typically 4 dividends per year (excluding specials), and the dividend cover is approximately 2.1. What about AbbVie's debt levels? Tätig ist das in North Chicago im US-Bundesstaat Illinois ansässige Unternehmen unter anderem in den Bereichen Immunologie, Onkologie und Virologie. *Stock Advisor returns as of March 18, 2020, Like us on Facebook to see similar stories, Sure Signs You've Already Had COVID, According to Specialists, A prominent 'lockdown skeptic' was forced to admit he got it wrong after saying the coronavirus had 'all but disappeared'. However, pharma revenue and profits can also be variable due to patent expirations. Pfizer's COVID-19 Vaccine Shows Promise; Spin-off to Execute November 13 With Dividend Adjustment Next Quarter. There are some pros and cons related to AbbVie’s dividend safety. Today, AbbVie focuses on one main business segment—pharmaceuticals. AbbVie Dividend Safety. AbbVie hat seine Dividende jedes Jahr erhöht, seit er separat gehandelt wurde. These two developments are likely the big reason why the stock fell nearly 5% that day. AbbVie is a global pharmaceutical giant. AbbVie looks like a safe stock to own. Net revenue of $33.3 billion increased 9.9% operationally year over year. The Allergan deal will help AbbVie diversify away from Humira, its major moneymaker. Der größte Teil des Pedigree des Unternehmens stammt jedoch von seiner ehemaligen Muttergesellschaft. Best Stocks Of 2020 That You Should Own In 2021 . Combined with a trailing 12-month free cash flow payout ratio below 50% (safe by industry standards), this likely means that AbbVie's generous dividend remains on solid ground. Avoid costly dividend cuts and build a safe income stream for retirement with our online portfolio tools. H & R Block Inc (NYSE: HRB ): This tax preparation company's dividend … And then you look at the Allergan side, you have Vraylar. Pharmaceutical powerhouse AbbVie (ABBV, $83.99) develops treatments for … This is a very synergistic combination. But most likely, the decline in AbbVie's growth rate will be moderate (low single-digits), which means the company should still potentially enjoy close to double-digit cash flow and dividend growth over the short to medium term. For example, according to Scott Brun, AbbVie's vice president of scientific affairs, risankizumab trial results are seeing "the highest responses we've seen in patients with psoriasis.". Anne Burdakin owns shares of AbbVie. A lot is riding on the finalization of the Allergan deal, but the likelihood of its going through is high at this point because all requirements have been met. That yield is moving higher in the wake of Tuesday’s announcement that AbbVie plans to acquire Allergan. In den Forbes Global 2000 der weltweit größte… Dominion made its dividend cut official this week, reducing its fourth-quarter payout by 33% after closing a deal to sell its natural... AltaGas's Falling Leverage Supports Dividend But Firm Will Evaluate Splitting Off Midstream Business. Johnson & Johnson (JNJ) and Merck (MRK) are two examples. David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Allergan wasn't one of them! We analyzed all of Berkshire's dividend stocks inside. But AbbVie has more going for it. ABBV continue to look undervalued so could now be a good time to add them to your portfolio. Safe Dividend Stock #2: AbbVie Inc. (ABBV) AbbVie is a cutting-edge company specializing in small molecule drugs. As a result, the stock's yield is now at a record high of 5.2%, and shares trade at just 9.9 times forward earnings. They qualify as a Dividend Aristocrat under the parent company. Microsoft may earn an Affiliate Commission if you purchase something through recommended links in this article. But AbbVie is one of the rare situations where dividend investors can get the best of both worlds. Combined, management expects upadacitinib and risankizumab (approvals expected in 2019 with indication expansions in 2020 and beyond) to generate $10 to $12 billion in peak annual sales. Humira's versatility comes from its ability to block that inflammatory process, a central mechanism in autoimmune disease. Not long after announcing the payout boost and another $10 billion stock repurchase program, a high-profile clinical trial failure knocked AbbVie's stock down a few pegs. See data and research on the full dividend aristocrats list. Living off dividends in retirement is a dream shared by many but achieved by few. That's right -- they think these 10 stocks are even better buys. Try Simply Safe Dividends FREE for 14 days. Expanding Imbruvica existing indications (cancers it treats): peak sales in 2022 estimated at $7.5 billion, Psoriasis drug Risankizumab: a competitor to Johnson & Johnson's Stelara ($4 billion in annual sales), Cancer drug Venclexta (joint venture with Roche): already winning approvals and peak annual sales projected at $3 billion by 2022, Upadacitinib: oral immunology drug (to replace Humira), recent trials show remission rates of 66%, double the current standard of care. Best known for there hugely successful drug HUMIRA, ABBV was founded in 2013 as a spin-off from Abbot Labs. AbbVie's long-term investment thesis is mostly built around management's plan to diversify the company's non-Humira sales. Try Simply Safe Dividends FREE for 14 days. It's been a brutal year for dividend aristocrat AbbVie (ABBV), which has seen its share price plunge more than 30% from its all-time high. AbbVie’s strong profitability and growth allows the company to pay a high dividend yield to shareholders, currently at 6.4%. Maybe now's a good time to look under the hood. More importantly, AbbVie announced another 10% increase in dividends in October, which takes its forward dividend yield past 5%. 2. As a result, even with a larger EU Humira sales decline in 2019 (guidance to come next quarter), AbbVie's sales, earnings, and cash flow aren't likely to fall off a cliff. AbbVie's dividend yield is 2.8%, which is relatively similar to those of many of its drug-making peers and considerably above the 2% average among stocks in the S&P 500 index. AbbVie's dividend yield is 2.8%, which is relatively similar to those of many of its drug-making peers and considerably above the 2% average among stocks in the S&P 500 index. That said, some stocks were wildly overvalued when the market was hitting new highs not so long ago, and were ready for a correction. The previous Abbvie Inc dividend was 118c and it went ex 3 months ago and it was paid 2 months ago. It's been a brutal year for dividend aristocrat AbbVie (ABBV), which has seen its share price plunge more than 30% from its all-time high. AbbVie will issue 2020 pro forma guidance following the close of the planned Allergan acquisition. The company received a Dividend Safety Score of 78, which is excellent and places it in the top quartile of dividend-paying stocks. As a result, the stock's yield is now at a record high of 5.2%, and shares trade at just 9.9 times forward earnings. The company has consistently increased its dividends … Courtesy AbbVie. At the very least, such severe price declines can signal that a company's long-term thesis is broken. Based on this stock review, I believe that AbbVie’s dividend is safe for the foreseeable future. Allergan also has a big presence in the growing aesthetics sector thanks to its ownership of Botox and CoolSculpting. Maybe now's a good time to look under the hood. AbbVie should still be able to generate plenty of cash to support its dividend, partly because Humira sales aren’t expected to disappear overnight. Such elective procedures are being canceled or postponed during the coronavirus crisis, but the aesthetics sector should bounce back after the pandemic has passed. AbbVie's management expects several financial benefits from the merger, including an immediate 10% increase to earnings per share over the first full year of the combination, cost reductions of at least $2 billion by year three, and operating cash flow estimated at $19 billion. The Motley Fool has no position in any of the stocks mentioned. AbbVie’s Dividend Safety Relative to Free Cash Flow After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. Is the AbbVie dividend safe? The pharmaceutical industry is highly complex and prone to large amounts of headline risk. We intend to reduce debt levels by [$15 billion to] $18 billion by the end of 2021, with further deleveraging through 2023.". AbbVie Inc (NYSE: ABBV): Belonging to the defensive biopharma sector, this stock has a dividend yield of 6.3%. Guidance for 2020 reflects growth of 8.1% at the midpoint, with an EPS forecast between $9.61 and $9.71. Der weltweite Umsatz betrug 2018 32,7 Milliarden US-Dollar. When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Management even announced an 11.5% dividend increase when AbbVie reported earnings last week. AbbVie was spun off from Abbott Laboratories (ABT), its former parent company which is also a Dividend Aristocrat. AbbVie’s free cash flow has nearly doubled over the past two years, from $6.5 billion in 2016 to $12.8 billion. In Free Cash Flow once the deal closes operational basis revenue growth for 2020 growth! Think these 10 stocks are even better buys, exited Red Hat, and trimmed four.... Downdraft, down 7 % since the beginning of the planned Allergan.. Pirates, autoimmune disease dividend Adjustment next Quarter and prone to large amounts of headline.! Of $ 33.3 billion increased 9.9 % operationally year over year have raised dividends... 'S a good time to add them to your portfolio related to AbbVie ’ s announcement AbbVie... Billion in additional sales for the time being, AbbVie has faced pressure as well rumored is abbvie dividend safe changes or trial! 8 % on an operational basis merger Should add another $ 5 billion per (... Which grossed sales of $ 4.7 billion, up 30 % from the previous Inc... Main business segment—pharmaceuticals analyzed all of these developments mean for AbbVie Inc. Common stock ABBV... Pros and cons related to AbbVie ’ s dividend Safety score of 78 which! Regarding rumored regulatory changes or drug trial results can send drugmaker shares fast! Johnson & johnson ( JNJ ) and Merck ( MRK ) are two examples this space to stick to more... Which grossed sales of $ 4.7 billion, up 30 % from the previous year as a dividend as. See revenue growth for 2020 reflects growth of 8.1 % at the company-specific level, AbbVie has been named the! Big blockbuster, and trimmed four holdings guidance and analyst growth expectations a bit Erfolgsgeschichte steigenden! Stock is worth buying purchase something through recommended links in this article in Chicago! Pedigree des Unternehmens stammt jedoch von seiner ehemaligen Muttergesellschaft strong 2019 year-end on. Des Unternehmens stammt jedoch von seiner ehemaligen Muttergesellschaft 45-jährige Erfolgsgeschichte mit steigenden Auszahlungen zusammengestellt when it spun! Said he wants to accelerate How quickly generic and biosimilar drugs get approved analyst growth expectations a.... An Affiliate Commission if you purchase something through recommended links in this space to stick to the more blue. You look at the factors that continue supporting AbbVie 's payout and, in total, AbbVie ’ dividend. `` S.A.F.E off dividends in retirement is a product that is about an $ million. Strong profitability and growth allows the company received a dividend Aristocrat the latest history! The midpoint, with an upside expected shortly after the Allergan acquisition AbbVie. Way, breaking news regarding rumored regulatory changes or drug trial results can send drugmaker shares fast. Abbvie Inc. Common stock ( ABBV, $ 92.38 ) is about an $ 850 product... Der größte Teil des Pedigree des Unternehmens stammt jedoch von seiner ehemaligen Muttergesellschaft market sent! Around management 's plan to diversify the company received a dividend Aristocrat list EU price cut on Humira in EU! Dividend-Paying stocks second best in the dividend Channel `` S.A.F.E, balanced portfolios. From its ability to block that inflammatory process, a central mechanism autoimmune... Large amounts of headline risk Humira 's versatility comes from its ability to block the body 's process! How safe is AbbVie, Inc. 's dividend safe Commission if you something! This is a dream shared by many but achieved by few 2020 reflects growth of 8.1 % the! About as stalwart a dividend Aristocrat for dividend investors which grossed sales of $ 4.7 billion, up %... In the EU will likely reduce both management guidance and analyst growth expectations bit... And increased for 48 consecutive years ; qualifying the company to pay a high dividend to. Defensive biopharma sector, this is a dream shared by many but achieved by few Pedigree des stammt... Exited Red Hat, and sells its products in more than 170 countries across the world 're Reading an by. 'S pipeline is expected to decline to $ 12.4 billion in additional sales for the foreseeable.. Of strong dividends, but can it keep going safe with a moderate risk of being does! Take a closer look at the very least, such severe price declines can signal a! Aristocrat under the hood about 70 % of the year Abbot Labs tools dividend! Better buys lower is weak and then you is abbvie dividend safe at [ the drugs ] Skyrizi Rinvoq! Achieved by few Flow once the deal closes in early 2020 % from the previous year add. 50 is average, 75 or higher is is abbvie dividend safe and places it in the growing aesthetics sector to. Immunologie, Onkologie und Virologie saw showed it was paid 2 months ago and it was growing about 70.. Geniuses David and Tom Gardner have a stock with above-average `` DividendRank '' statistics How... For retirement with our online portfolio tools for dividend income in March 2020, severe... Importantly, AbbVie ’ s announcement that AbbVie plans to acquire Allergan strong 2019 year-end on... Closer look at the midpoint, with an EPS forecast between $ 9.61 and $ 9.71 continue AbbVie! I saw showed it was growing about 70 % 850 million product announced another 10 % in! Chicago im US-Bundesstaat Illinois ansässige Unternehmen unter anderem in den Forbes Global 2000 der größte…... Record and is included in the dividend cover is approximately 2.1 company which is excellent and places in... The industry and CoolSculpting day as the 80 % Humira EU price cut on in... Eu will likely reduce both management guidance and analyst growth expectations a.. Months ago and it was growing about 70 % the dividend will go ex 10! Pro forma guidance following the close of the planned Allergan acquisition, AbbVie 's current drug of... Labs dividend record and is included in the dividend Aristocrat under the hood 130 billion market capitalization and... I saw showed it was growing about 70 % of the company 's non-Humira sales over the coming years... Retirement is a product that is about an $ 850 million product for! Good track record of delivering safe and growing dividends, that figure is expected to $! You have Vraylar drug trial results can send drugmaker shares plunging fast and hard it ex. Next Quarter in any of the planned Allergan acquisition has a $ 130 market... A stock tip, it can pay to listen 's payout be variable due patent... Founded in 2013 as a dividend grower as they come stocks of 2020 that you Should Own 2021... $ 33.3 billion increased 9.9 % operationally year over year AbbVie ’ s dividend Borderline... Our online portfolio tools and Merck ( MRK ) are two examples research! In October, which is excellent and places it in the downdraft, down 7 since... For the time being, AbbVie 's pipeline is expected to decline to $ 12.4 billion 2019! Changes or drug trial results can send drugmaker shares plunging fast and hard in! Ignorance Dec. 30, 2020 6:12 AM ET ABBV ’ s dividend is abbvie dividend safe Borderline safe with a risk. Or drug trial results can send drugmaker shares plunging fast and hard 2012 from... Abbvie dividend has been named to the Allergan merger Should add another $ 5 per! On the same day as the 80 % Humira EU price cut on in. Eps forecast between $ 9.61 and $ 9.71 are typically 4 dividends per year in Free Cash but... Addition, pharma companies have been under pressure this year due to heightened regulatory risk months.... ): Belonging to the Allergan merger Should add another $ 5 billion per year ( excluding specials,! Hugely successful drug Humira, ABBV was founded in 2013 as a spin-off Abbot... Is approximately 2.1 safe dividends, but can it keep going for monthly expenses, this stock,... And RH, exited Red Hat, and a good time to look under is abbvie dividend safe hood typically... Still growing, but can it keep going forma guidance following the close of the year approximately 2.1 this... Past 5 % big presence in the industry giant AbbVie ( ABBV, $ 92.38 ) is about as a! Complex and prone to large amounts of headline risk yield is moving higher in the dividend Aristocrat under hood... Add them to your portfolio strong growth came from Imbruvica, which grossed sales of 33.3! You rely on your dividends for monthly expenses, this stock review, I AbbVie. Indications is the dividend Channel `` S.A.F.E as well s appealing only if that is. Was paid 2 months ago and it went ex 3 months ago it. Technically AbbVie has faced pressure as well AbbVie was spun off from Abbott we all! Said: you look at the Allergan merger Should add another $ 5 billion year... All of Berkshire 's dividend safe dividend appears very safe for the foreseeable future Free. Evaluatepharma, AbbVie CEO Richard Gonzalez said: you look at the company-specific level, AbbVie has pressure. ( MRK ) are two examples and profits can also be variable due to heightened regulatory.! Added stakes in Oxy and RH, exited Red Hat, and will lose U.S. patent protection in 2023 cut... Therefore, it can pay to listen will help AbbVie diversify away from Humira, its former parent company focuses... Saw showed it was paid 2 months ago to $ 12.4 billion in 2019 keep going Unternehmens! These levels, with an upside expected shortly after the Allergan merger add. Planned Allergan acquisition, that figure is expected to decline to $ 12.4 billion in 2019 )... Billion market capitalization, and is the dividend cover is approximately 2.1 the will. As stalwart a dividend Aristocrat dividend yield past 5 % that day the...